Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Feb 3;2(2):CD005254.
doi: 10.1002/14651858.CD005254.pub4.

Surfactant for pulmonary haemorrhage in neonates

Abdul Aziz  1 , Arne Ohlsson  2
Affiliations
Meta-Analysis

Surfactant for pulmonary haemorrhage in neonates

Abdul Aziz et al. Cochrane Database Syst Rev. .

Abstract

Background: In the 1960s and 1970s, pulmonary haemorrhage (PH) occurred mainly in full-term infants with pre-existing illness with an incidence of 1.3 per 1000 live births. Risk factors for PH included severity of illness, intrauterine growth restriction, patent ductus arteriosus (PDA), coagulopathy and the need for assisted ventilation. Presently, PH occurs in 3% to 5% of preterm ventilated infants with severe respiratory distress syndrome (RDS) who often have a PDA and have received surfactant. The cause of PH is thought to be due to rapid lowering of intrapulmonary pressure, which facilitates left to right shunting across a PDA and an increase in pulmonary blood flow. Retrospective case reports and one prospective uncontrolled study have shown promising results for surfactant in treating PH.

Objectives: To evaluate the effect of surfactant treatment compared to placebo or no intervention on mortality and morbidities in neonates with PH.

Search methods: For this update The Cochrane Library, Issue 2, 2012; MEDLINE; EMBASE; CINAHL; Clinicaltrials.gov; Controlled-trials.com; proceedings (2000 to 2011) of the Annual Meetings of the Pediatric Academic Societies (Abstracts2View) and Web of Science were searched on 8 February 2012.

Selection criteria: Randomised or quasi-randomised controlled trials that evaluated the effect of surfactant in the treatment of PH in intubated term or preterm (< 37 weeks) neonates with PH. Infants were included up to 44 weeks' postmenstrual age. The interventions studied were intratracheal instillation of surfactant (natural or synthetic, regardless of dose) versus placebo or no intervention.

Data collection and analysis: If studies were identified by the literature search, the planned analyses included risk ratio, risk difference, number needed to treat to benefit or to harm for dichotomous outcomes, and mean difference for continuous outcomes, with their 95% confidence intervals. A fixed-effect model would be used for meta-analyses. The risk of bias for included trials would be assessed. Heterogeneity tests, including the I2 statistic, would be performed to assess the appropriateness of pooling the data and the results would be reported.

Main results: No trials were identified.

Authors' conclusions: No randomised or quasi-randomised trials that evaluated the effect of surfactant in PH were identified. Therefore, no conclusions from such trials can be drawn. In view of the promising results from studies with less strict study designs than a randomised controlled trial, there is reason to conduct further trials of surfactant for the treatment of PH in neonates.

PubMed Disclaimer

Conflict of interest statement

None.

Update of

References

References to studies excluded from this review

Lacaze‐Masmonteil 2007 {published data only}
    1. Lacaze‐Masmonteil T. Expanded use of surfactant therapy in newborns. Clinics in Perinatology 2007;34:179‐89. - PubMed

Additional references

Abdel‐Latif 2010
    1. Abdel‐Latif ME, Osborn DA. Nebulised surfactant for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008310] - DOI - PMC - PubMed
Abdel‐Latif 2011
    1. Abdel‐Latif ME, Osborn DA. Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD008309.pub2] - DOI - PubMed
Abdel‐Latif 2011a
    1. Abdel‐Latif ME, Osborn DA. Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD008311.pub2] - DOI - PubMed
Amizuka 2003
    1. Amizuka T, Shimizu H, Niida Y, Ogawa Y. Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. European Journal of Pediatrics 2003;162:697‐702. - PubMed
Cole 1973
    1. Cole VA, Normand IC, Reynolds EO, Rivers RP. Pathogenesis of hemorrhagic pulmonary edema and massive pulmonary hemorrhage in the newborn. Pediatrics 1973;51:175‐87. - PubMed
Dargaville 2002
    1. Dargaville PA, Mills JF, Soll R. Therapeutic lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003486] - DOI - PMC - PubMed
El Shahed 2007
    1. Shahed AI, Dargaville P, Ohlsson A, Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD002054.pub2] - DOI - PubMed
Findlay 1995
    1. Findlay RD, Taeusch HW, David‐Cu R, Walther FJ. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatric Research 1995;37:26‐30. - PubMed
Finer 2004
    1. Finer NN. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatric Respiratory Reviews 2004;5:Suppl A:S289‐97. - PubMed
Haas 2006
    1. Haas NA, Kulasekaran K, Camphausen CK. Successful use of surfactant to treat severe intrapulmonary hemorrhage after iatrogenic lung injury ‐ a case report. Pediatric Critical Care Medicine 2006;7:583‐5. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org 2011.
Holm 1987
    1. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. Journal of Applied Physiology 1987;63:1434‐42. - PubMed
Pandit 1995
    1. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995;95:32‐6. - PubMed
Pandit 1999
    1. Pandit PB, O'Brien K, Asztalos E, Colucci E. Dunn MS. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant. Archives of Disease in Childhood. Fetal and Neonatal Edition 1999;81:F40‐4. - PMC - PubMed
Pappin 1994
    1. Pappin A, Shenker N, Hack M, Redline RW. Extensive intraalveolar pulmonary hemorrhage in infants dying after surfactant therapy. Journal of Pediatrics 1994;124:621‐6. - PubMed
Papworth 2001
    1. Papworth S, Cartlidge PHT. Pulmonary haemorrhage. Current Paediatrics 2001;11:167‐71.
Pfister 2007
    1. Pfister RH, Soll R, Wiswell TE. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006069.pub3] - DOI - PubMed
Pfister 2009
    1. Pfister RH, Soll R, Wiswell TE. Protein‐containing synthetic surfactant versus protein‐free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD006180.pub2] - DOI - PubMed
Raju 1993
    1. Raju TN, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. Journal of Pediatrics 1993;123:603‐10. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rojas‐Reyes 2012
    1. Rojas‐Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD000510.pub2] - DOI - PMC - PubMed
Seger 2009
    1. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007836] - DOI - PMC - PubMed
Sinclair 1992
    1. Sinclair J, Bracken M. Effective Care of the Newborn. Oxford University Press, 1992.
Singh 2011
    1. Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta‐analysis. Pediatrics 2011; Vol. 128:e1588‐95. - PubMed
Soll 1997
    1. Soll RF, Ozek E. Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 1997, Issue 4. [DOI: 10.1002/14651858.CD000511] - DOI - PMC - PubMed
Soll 1998
    1. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews 1998, Issue 3. [DOI: 10.1002/14651858.CD001149] - DOI - PMC - PubMed
Soll 1999
    1. Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD001456] - DOI - PubMed
Soll 2001
    1. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD000144] - DOI - PubMed
Soll 2009
    1. Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000141.pub2] - DOI - PubMed
Soll 2010
    1. Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001079.pub2] - DOI - PMC - PubMed
Stevens 2007
    1. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003063.pub3] - DOI - PMC - PubMed
Tan 2012
    1. Tan K, Lai NM, Sharma A. Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008155.pub2] - DOI - PMC - PubMed
Van Houten 1994
    1. Houten J, Long W, Mullett M, Finer N, Derleth D, McMurray B, et al. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation. Journal of Pediatrics 1992;120:S40‐4. - PubMed
Wiswell 2001
    1. Wiswell TE. Expanded uses of surfactant therapy. Clinics in Perinatology 2001;28:695‐711. - PubMed

References to other published versions of this review

Aziz 2008
    1. Aziz A, Ohlsson A. Surfactant for pulmonary hemorrhage in neonates. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005254.pub2] - DOI - PubMed

Publication types

Substances